ONT - Ticker AI Digest

Oxford Nanopore Technologies Ltd 📰 1
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
Oxford Nanopore Technologies Ltd in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
ONT Data 2026-01-12 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (ONT) 1
ONT 06:01
Oxford Nanopore Technologies Ltd
Full Year Trading Update and Notice of Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Oxford Nanopore Technologies plc released a full-year trading update for 2025, reporting strong performance with revenue growth slightly ahead of guidance. The company expects revenue of approximately £223-£224 million, representing a 22% increase on a reported basis and 24% at constant currency, exceeding its 20-23% guidance range. Growth was broad-based across all geographies (EMEAI, APAC, AMR), customer end markets (Clinical, BioPharma, Applied Industrial, Research), and product categories, led by the PromethION range. Clinical revenue grew by ~60%, BioPharma by ~30%, Applied Industrial by ~27%, and Research by ~15% despite funding pressures.
The company ended 2025 with approximately £302 million in cash and liquid investments, ahead of consensus expectations, supported by improved working capital. Oxford Nanopore remains well-capitalized to execute its strategy and continue its path to profitability. The preliminary annual results for 2025 will be announced on March 2, 2026, followed by a virtual presentation and Q&A session. The update highlights the companys progress in delivering accessible, scalable DNA and RNA analysis technology, with applications across healthcare, food, agriculture, and more.
**Key Highlights**
Revenue£223-£224 million (22% reported, 24% constant currency growth)
Broad-based growth across regionsmarketsand products
Strong cash position£302 million
Preliminary results announcementMarch 2, 2026
Below is the HTML table code comparing the financials and debt year-on-year based on the provided text: < lang="en">Oxford Nanopore Financials Comparison

Oxford Nanopore Technologies plc - Financials Comparison (FY24 vs FY25)

MetricFY2024FY2025Growth/Change
Revenue (£ million)183.2223 - 224~22% (reported) / ~24% (constant currency)
Cash, Cash Equivalents, and Liquid Investments (£ million)403.8302-25.2%
Clinical Revenue Growth (reported)N/A~60%N/A
BioPharma Revenue Growth (reported)N/A~30%N/A
Applied Industrial Revenue Growth (reported)N/A~27%N/A
Research Revenue Growth (reported)N/A~15%N/A
PromethION Range Growth (reported)N/A>40%N/A

Notes:

  • FY24 customer end market figures have been reclassified. No change to overall FY24 revenue.
  • Constant currency (CC) applies FY24 rates to FY25 results.
  • All percentages compare to the equivalent 2024 period.
### Explanation: 1. **Revenue**: Compares FY24 (£183.2 million) to FY25 (£223-£224 million) with growth rates provided. 2. **Cash and Liquid Investments**: Compares FY24 (£403.8 million) to FY25 (£302 million), showing a decrease. 3. **Revenue Growth by Segment**: Lists growth rates for Clinical, BioPharma, Applied Industrial, Research, and PromethION range for FY25. 4. **Notes**: Includes important footnotes for context, such as reclassification of FY24 figures and constant currency explanation. This table provides a clear year-on-year comparison of key financials and growth metrics.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
ONT 06:01
Oxford Nanopore Technologies Ltd
Full Year Trading Update and Notice of Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Oxford Nanopore Technologies plc released a full-year trading update for 2025, reporting strong performance with revenue growth slightly ahead of guidance. The company expects revenue of approximately £223-£224 million, representing a 22% increase on a reported basis and 24% at constant currency, exceeding its 20-23% guidance range. Growth was broad-based across all geographies (EMEAI, APAC, AMR), customer end markets (Clinical, BioPharma, Applied Industrial, Research), and product categories, led by the PromethION range. Clinical revenue grew by ~60%, BioPharma by ~30%, Applied Industrial by ~27%, and Research by ~15% despite funding pressures.
The company ended 2025 with approximately £302 million in cash and liquid investments, ahead of consensus expectations, supported by improved working capital. Oxford Nanopore remains well-capitalized to execute its strategy and continue its path to profitability. The preliminary annual results for 2025 will be announced on March 2, 2026, followed by a virtual presentation and Q&A session. The update highlights the companys progress in delivering accessible, scalable DNA and RNA analysis technology, with applications across healthcare, food, agriculture, and more.
**Key Highlights**
Revenue£223-£224 million (22% reported, 24% constant currency growth)
Broad-based growth across regionsmarketsand products
Strong cash position£302 million
Preliminary results announcementMarch 2, 2026
Below is the HTML table code comparing the financials and debt year-on-year based on the provided text: < lang="en">Oxford Nanopore Financials Comparison

Oxford Nanopore Technologies plc - Financials Comparison (FY24 vs FY25)

MetricFY2024FY2025Growth/Change
Revenue (£ million)183.2223 - 224~22% (reported) / ~24% (constant currency)
Cash, Cash Equivalents, and Liquid Investments (£ million)403.8302-25.2%
Clinical Revenue Growth (reported)N/A~60%N/A
BioPharma Revenue Growth (reported)N/A~30%N/A
Applied Industrial Revenue Growth (reported)N/A~27%N/A
Research Revenue Growth (reported)N/A~15%N/A
PromethION Range Growth (reported)N/A>40%N/A

Notes:

  • FY24 customer end market figures have been reclassified. No change to overall FY24 revenue.
  • Constant currency (CC) applies FY24 rates to FY25 results.
  • All percentages compare to the equivalent 2024 period.
### Explanation: 1. **Revenue**: Compares FY24 (£183.2 million) to FY25 (£223-£224 million) with growth rates provided. 2. **Cash and Liquid Investments**: Compares FY24 (£403.8 million) to FY25 (£302 million), showing a decrease. 3. **Revenue Growth by Segment**: Lists growth rates for Clinical, BioPharma, Applied Industrial, Research, and PromethION range for FY25. 4. **Notes**: Includes important footnotes for context, such as reclassification of FY24 figures and constant currency explanation. This table provides a clear year-on-year comparison of key financials and growth metrics.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 3
ONT 06:01
Oxford Nanopore Technologies Ltd
Full Year Trading Update and Notice of Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Oxford Nanopore Technologies plc released a full-year trading update for 2025, reporting strong performance with revenue growth slightly ahead of guidance. The company expects revenue of approximately £223-£224 million, representing a 22% increase on a reported basis and 24% at constant currency, exceeding its 20-23% guidance range. Growth was broad-based across all geographies (EMEAI, APAC, AMR), customer end markets (Clinical, BioPharma, Applied Industrial, Research), and product categories, led by the PromethION range. Clinical revenue grew by ~60%, BioPharma by ~30%, Applied Industrial by ~27%, and Research by ~15% despite funding pressures.
The company ended 2025 with approximately £302 million in cash and liquid investments, ahead of consensus expectations, supported by improved working capital. Oxford Nanopore remains well-capitalized to execute its strategy and continue its path to profitability. The preliminary annual results for 2025 will be announced on March 2, 2026, followed by a virtual presentation and Q&A session. The update highlights the companys progress in delivering accessible, scalable DNA and RNA analysis technology, with applications across healthcare, food, agriculture, and more.
**Key Highlights**
Revenue£223-£224 million (22% reported, 24% constant currency growth)
Broad-based growth across regionsmarketsand products
Strong cash position£302 million
Preliminary results announcementMarch 2, 2026
Below is the HTML table code comparing the financials and debt year-on-year based on the provided text: < lang="en">Oxford Nanopore Financials Comparison

Oxford Nanopore Technologies plc - Financials Comparison (FY24 vs FY25)

MetricFY2024FY2025Growth/Change
Revenue (£ million)183.2223 - 224~22% (reported) / ~24% (constant currency)
Cash, Cash Equivalents, and Liquid Investments (£ million)403.8302-25.2%
Clinical Revenue Growth (reported)N/A~60%N/A
BioPharma Revenue Growth (reported)N/A~30%N/A
Applied Industrial Revenue Growth (reported)N/A~27%N/A
Research Revenue Growth (reported)N/A~15%N/A
PromethION Range Growth (reported)N/A>40%N/A

Notes:

  • FY24 customer end market figures have been reclassified. No change to overall FY24 revenue.
  • Constant currency (CC) applies FY24 rates to FY25 results.
  • All percentages compare to the equivalent 2024 period.
### Explanation: 1. **Revenue**: Compares FY24 (£183.2 million) to FY25 (£223-£224 million) with growth rates provided. 2. **Cash and Liquid Investments**: Compares FY24 (£403.8 million) to FY25 (£302 million), showing a decrease. 3. **Revenue Growth by Segment**: Lists growth rates for Clinical, BioPharma, Applied Industrial, Research, and PromethION range for FY25. 4. **Notes**: Includes important footnotes for context, such as reclassification of FY24 figures and constant currency explanation. This table provides a clear year-on-year comparison of key financials and growth metrics.
ONT 06:01
Oxford Nanopore Technologies Ltd
Upcoming Investor Events and Conferences
ONT 14:01
Oxford Nanopore Technologies Ltd
Issue of Equity and Total Voting Rights

Today's AI

Today's AI Starts With News

1 live catalyst is opening Today’s AI for ONT.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2026-01-12 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
1 Today
Front Of Desk
Oxford Nanopore Technologies Ltd has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
Single-Ticker Today's AI
ONT signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for Oxford Nanopore Technologies Ltd. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full ONT Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for ONT on 2026-01-12.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
1.2B
Enterprise Value
1.5B
Public Float
41.5
Broker Target
199.167
Shares Out
967.4M
Long Interest
82
Short Interest
18
Exchange
LSE
Currency Code
GBX
ISIN
GB00BP6S8Z30
Market
None
Sector
Personal Care, Drug and Grocery Stores
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

1 live alert now opens the financials desk for ONT.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2026-01-12 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
1 Alerts
Front Of Desk
Oxford Nanopore Technologies Ltd has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-03-02
Net Debt
-139.6M
Cash
181.1M
EPS
-0.15
Net Income
-145.2M
Revenue
223.9M
Enterprise Value
1.5B
Trailing PE
-
Forward PE
-
Price Sales TTM
5.4698
Price Book MRQ
2.6434
EV Revenue
4.5149
EV EBITDA
-8.8899
Financial Forecastist

Improving financial engine

Revenue is accelerating +307.0% against the prior comparable period. Net margin is expanding by 24.9 pts. Net debt is coming down +13.8%.

Revenue +307.0% Net Income +192.8% FCF +26.3% Current Ratio 3.56x Forward Rev 105.1M
Improving
Quarter Revenue
171.1M
+307.0%
vs prior comparable quarter
Net Margin
-63.9%
+24.9 pts
profitability pulse
Free Cash Flow
-40.9M
+26.3%
cash conversion
Net Debt / EBITDA
1.9x
-13.8%
lower is cleaner
Revenue Engine

Latest quarter printed 171.1M with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at -109.3M and the margin profile is broadening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 181.1M while net debt is -139.6M. The leverage stack is cleaning up.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q1 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q2 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q3 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q2 2025
Consensus
105.1M
Revenue Path
0.07
EPS / Earnings
Growth cue -
FY 2026
Consensus
274.1M
Revenue Path
-0.11
EPS / Earnings
Growth cue +0.1%
FY 2027
Consensus
345.1M
Revenue Path
-0.08
EPS / Earnings
Growth cue +0.3%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q4 2025 171.1M -109.3M -40.9M -139.6M
Q2 2025 52.8M -35.9M -25.4M -150.0M
Q4 2024 99.1M -71.5M -59.1M -153.6M
Q2 2024 84.1M -74.7M -64.8M -115.3M
Q1 2024 42.0M -37.3M -32.4M -162.0M
Q4 2023 83.7M -84.4M -83.1M -178.9M

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 223.9M -145.2M -105.5M -66.3M
FY 2024 183.2M -146.2M -93.1M -123.8M
FY 2023 169.7M -154.5M -105.7M -164.6M
FY 2022 198.6M -91.0M -49.7M -91.6M
FY 2021 133.7M -167.6M -140.3M -84.6M

Structure DNA

Market Structure DNA

Balanced Structure profile with trend broken

Price is 18.7% through the 52-week range, +3.5% vs 50DMA and -14.6% vs 200DMA. 82.8% of the register is locked by institutions and insiders, leaving 17.2% free float. Capital rhythm reads no cadence with forward yield near 0.0% and payout around 0.0%.

Trend broken Institutional gravity Moderate income rhythm As Of 2026-04-19
Balanced Structure
Structure Score
48.2 / 100
Balanced Structure
Trend Stack
+3.5% / -14.6%
vs 50DMA / 200DMA
52W Position
18.7%
auction position inside the yearly range
Ownership Lock
82.8%
40.5% institutions | 42.3% insiders
Pressure Pocket
121.0% short float
Short ratio 0.0x | monthly -
Capital Rhythm
No cadence
Yield 0.0% | payout 0.0%
Trend Runway

Implied spot is 126.60 with the stock +3.5% vs 50DMA and -14.6% vs 200DMA. The tape is sitting 18.7% through the 52-week range, which frames the regime as trend broken.

Ownership Register

Institutions hold about 40.5% and insiders about 42.3%, locking roughly 82.8% of the register and leaving 17.2% in free float. That reads as institutional gravity.

Pressure Pocket

Short pressure is running near 121.0% of float with short ratio 0.0x and monthly change -. That gives us a read on whether the tape is clean, crowded, or coiled.

Capital Rhythm

Dividend cadence reads no cadence with - event(s) in the last full year, a five-year average of -, and stability score 0.0/100. Forward yield sits near 0.0% while payout is around 0.0%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

No cadence
Year Dividend Count Context
Dividend history has not been normalized yet.

Structure Facts

Live Snapshot
Implied Spot
126.60
derived from market cap / shares
52W High
224.80
upper auction edge
52W Low
104.00
lower auction edge
Beta
0.88
volatility character
Shares Out
967.4M
fully diluted count
Shares Float
401.3M
tradable register
Shares Short
0
borrowed stock
Short Ratio
0.0x
days-to-cover style read
Ex-Dividend
-
next ex-date not supplied
Dividend Pay
-
payment date not supplied
Last Split
-
split date not supplied

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
31.9483
Institutions As Of
2025-07-29
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
23
Sale Director Dealing
6
Purchase TR1
12
Sale TR1
2
Broker Coverage Rows
12
Institution Holders Tracked
3
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for ONT, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2026-01-12 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
1 Today
Catalyst Pulse
Oxford Nanopore Technologies Ltd has fresh news flow live now, so the tape is framing the chart workspace below.
AI Charts Studio
ONT Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-01-12 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
Indicators0
Technicals0
AI Forecast -9.66%
RSI Gauge
Price Change
AI Forecast